These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35290662)

  • 21. Immune-related hematologic adverse events in the context of immune checkpoint inhibitor therapy.
    Saliba AN; Xie Z; Higgins AS; Andrade-Gonzalez XA; Fuentes-Bayne HE; Hampel PJ; Kankeu Fonkoua LA; Childs DS; Rakshit S; Bezerra ED; Kommalapati A; Lou Y; Rivera CE; Price KA; Chintakuntlawar A; Yan Y; Schwecke AJ; Block MS; Thanarajasingam U; Thanarajasingam G; Wolanskyj-Spinner AP; Marshall AL; Kottschade LA; Go RS; Al-Kali A
    Am J Hematol; 2021 Oct; 96(10):E362-E367. PubMed ID: 34137072
    [No Abstract]   [Full Text] [Related]  

  • 22. The effect of baseline eczema or psoriasis on the morphology of cutaneous immune-related adverse events due to immune checkpoint inhibitor therapy.
    Belzer A; Mortlock RD; Pach J; Cohen JM; Leventhal JS
    J Am Acad Dermatol; 2023 May; 88(5):1198-1200. PubMed ID: 36634749
    [No Abstract]   [Full Text] [Related]  

  • 23. [Predictive Biomarkers of Immune-related Adverse Events Induced by Checkpoint Inhibitors in Malignancies].
    Tang H; Guan M; Sun Z; Bai CM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Dec; 42(6):825-830. PubMed ID: 33423733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of the Top 10 Most Common Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy.
    Schneider BJ; Lacchetti C; Bollin K
    JCO Oncol Pract; 2022 Jun; 18(6):431-444. PubMed ID: 35061502
    [No Abstract]   [Full Text] [Related]  

  • 25. Immune-related adverse events: what we've learned and where we're heading.
    Badran YR; Leet DE; Dougan M
    Expert Rev Anticancer Ther; 2020 Sep; 20(9):727-730. PubMed ID: 32726153
    [No Abstract]   [Full Text] [Related]  

  • 26. Immune checkpoint inhibitor-related dermatologic adverse events.
    Geisler AN; Phillips GS; Barrios DM; Wu J; Leung DYM; Moy AP; Kern JA; Lacouture ME
    J Am Acad Dermatol; 2020 Nov; 83(5):1255-1268. PubMed ID: 32454097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
    J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.
    Nagai H; Muto M
    Int J Clin Oncol; 2018 Jun; 23(3):410-420. PubMed ID: 29516216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cutaneous immune-related adverse events among Taiwanese cancer patients receiving immune checkpoint inhibitors link to a survival benefit.
    Cho YT; Lin YT; Yang CW; Chu CY
    Sci Rep; 2022 Apr; 12(1):7021. PubMed ID: 35487955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune-related cutaneous adverse events due to checkpoint inhibitors.
    Wang E; Kraehenbuehl L; Ketosugbo K; Kern JA; Lacouture ME; Leung DYM
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):613-622. PubMed ID: 33609771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of glucocorticoids in the management of immunotherapy-related adverse effects.
    Wang H; Zhou J; Guo X; Li Y; Duan L; Si X; Zhang L
    Thorac Cancer; 2020 Oct; 11(10):3047-3052. PubMed ID: 32893490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delayed dermatologic hypersensitivity reaction secondary to ipilimumab.
    Ludlow SP; Kay N
    J Immunother; 2015 May; 38(4):165-6. PubMed ID: 25839442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors.
    Park BC; Jung S; Chen ST; Dewan AK; Johnson DB
    Am J Clin Dermatol; 2022 Sep; 23(5):707-717. PubMed ID: 35708849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. "Skin rashes" and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management.
    Sollena P; Cappilli S; Federico F; Schinzari G; Tortora G; Peris K
    Hum Vaccin Immunother; 2022 May; 18(3):1889449. PubMed ID: 33759689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Why are immune adverse events so common with checkpoint inhibitor therapy?
    Lyubchenko T; Leung DYM; Goleva E
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):608-610. PubMed ID: 33774187
    [No Abstract]   [Full Text] [Related]  

  • 37. Do immune-related adverse events correlate with response to immune checkpoint inhibitors?
    Saleh K; Khalife-Saleh N; Kourie HR
    Immunotherapy; 2019 Mar; 11(4):257-259. PubMed ID: 30678551
    [No Abstract]   [Full Text] [Related]  

  • 38. Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.
    Chen CH; Yu HS; Yu S
    Curr Oncol; 2022 Apr; 29(4):2871-2886. PubMed ID: 35448208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Cutaneous Toxicity of Immune Checkpoint Inhibitors: A Narrative Review].
    Gomes N; Sibaud V; Azevedo F; Magina S
    Acta Med Port; 2020 May; 33(5):335-343. PubMed ID: 32416756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy.
    Keiser MF; Patel AB; Altan M
    Clin Lung Cancer; 2021 May; 22(3):195-200.e1. PubMed ID: 33637416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.